DGX vs PHAT · P/E 22, rev $5.94B vs rev $132.6M
Quest Diagnostics Incorporated (DGX) versus Phathom Pharmaceuticals Inc (PHAT) — a side-by-side from cached financials, not a winner call.
Quest Diagnostics Incorporated (DGX) is a diagnostics & research company listed on US.
Phathom Pharmaceuticals Inc (PHAT) is a biotechnology company listed on US.
Latest reported DGX revenue for 2026-06-30 was $5.94B. Net income was $572.0M. DGX currently screens at market cap $19.94B and trailing P/E 22.4.
Latest reported PHAT revenue for 2026-06-30 was $132.6M. Net income was -$48.0M. PHAT currently screens at market cap $622.7M.
DGX currently screens at market cap $19.94B and trailing P/E 22.4. PHAT currently screens at market cap $622.7M.
Not investment advice. Open the DGX and PHAT stock pages for the full models.
Not investment advice.